血紅素病治療市場：依藥物類型、疾病類型、通路和地區分類

Hemoglobinopathy Treatment Drugs Market, By Drug Type, By Disease Type, By Distribution Channel, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，血紅蛋白病治療市場在 2026 年將達到 57.4 億美元，預計到 2033 年將達到 102.4 億美元。預計從 2026 年到 2033 年，該市場將以 8.6% 的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	57.4億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	8.60%	預計金額（2033 年）	102.4億美元

血紅蛋白疾病是指所有與血紅蛋白相關的遺傳性疾病。這些疾病主要分為兩類：地中海型貧血症候群和結構性血紅素變異（異常血紅素）。地中海型貧血主要分為a型和b型，主要的結構性血紅素變異包括HbS、HbE和HbC。每類疾病中都存在許多亞型和組合。血紅素疾病的臨床症狀極為多樣，從輕度低色素性貧血到中度血液疾病，甚至嚴重、終身輸血依賴性貧血伴隨多重器官衰竭。對於嚴重地中海貧血，造血幹細胞移植是第一線治療方案。它並非根治性治療，而是一種症狀治療，需要終身定期輸血和鐵螯合療法。用於治療鐮狀細胞疾病症狀的藥物包括止痛藥、抗生素、血管緊張素轉換酶抑制劑和羥基脲。輸血應僅在絕對必要時才進行。目前，超過90%的患者能夠存活至成年。接受最佳治療的患者預期壽命為50至60歲。血紅素疾病是最常見的單基因遺傳疾病，也是全球主要健康問題之一，全球約有7%的人口為帶因者。這些疾病最初主要分佈於地中海地區以及亞洲和非洲的大片地區。國際移民潮已將其從這些地區傳播到世界各地。如今，在歐洲許多地區，血紅蛋白（Hb）異常已被列為地方流行病。

市場動態

主要市場參與者不斷推出新產品，以及併購的活性化，預計將推動全球血紅蛋白疾病治療市場的成長。例如，2022年8月8日，總部位於美國的跨國製藥和生物技術公司輝瑞（Pfizer Inc.）和總部位於美國的醫療保健公司Global Blood Therapeutics, Inc.宣布，雙方已達成最終協議，輝瑞將收購GBT。根據交易條款，輝瑞將以每股68.50美元的現金價格收購Global Blood Therapeutics, Inc.的所有已發行股份。此次交易後，包括債務在內，扣除收購的現金後，公司總價值約54億美元。兩家公司的董事會均一致批准了該交易。

本報告的主要特點

本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
本節根據各種參數（公司概況、產品系列、主要趨勢、財務表現、策略等）介紹全球血紅素疾病治療市場的主要公司。
《全球血紅蛋白病治療市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球血紅蛋白病治療市場中使用的各種策略矩陣來促進決策。

區域趨勢
- 北美洲
  - 介紹
  - 市場規模、預測與同比增速分析：按藥物類型分類
  - 市場規模、預測與同比增速分析：按疾病類型分類
  - 市場規模、預測及年增率分析：依分銷通路分類
  - 市場規模、預測與同比增速分析：按國家/地區分類
    - 美國
    - 加拿大
- 拉丁美洲
  - 介紹
  - 市場規模、預測與同比增速分析：按藥物類型分類
  - 市場規模、預測與同比增速分析：按疾病類型分類
  - 市場規模、預測及年增率分析：依分銷通路分類
  - 市場規模、預測與同比增速分析：按國家/地區分類
    - 巴西
    - 墨西哥
    - 阿根廷
    - 其他拉丁美洲國家
- 歐洲
  - 介紹
  - 市場規模、預測與同比增速分析：按藥物類型分類
  - 市場規模、預測與同比增速分析：按疾病類型分類
  - 市場規模、預測及年增率分析：依分銷通路分類
  - 市場規模、預測與同比增速分析：按國家/地區分類
    - 英國
    - 德國
    - 義大利
    - 法國
    - 西班牙
    - 俄羅斯
    - 其他歐洲國家
- 亞太地區
  - 介紹
  - 市場規模、預測與同比增速分析：按藥物類型分類
  - 市場規模、預測與同比增速分析：按疾病類型分類
  - 市場規模、預測及年增率分析：依分銷通路分類
  - 市場規模、預測與同比增速分析：按國家/地區分類
    - 中國
    - 印度
    - 日本
    - ASEAN
    - 澳洲
    - 韓國
    - 其他亞太國家
- 中東
  - 介紹
  - 市場規模、預測與同比增速分析：按藥物類型分類
  - 市場規模、預測與同比增速分析：按疾病類型分類
  - 市場規模、預測及年增率分析：依分銷通路分類
  - 市場規模、預測與同比增速分析：按國家/地區分類
    - 波灣合作理事會（GCC）國家
    - 以色列
    - 其他中東國家
- 非洲
  - 介紹
  - 市場規模、預測與同比增速分析：按藥物類型分類
  - 市場規模、預測與同比增速分析：按疾病類型分類
  - 市場規模、預測及年增率分析：依分銷通路分類
  - 市場規模、預測及年增率分析：依國家及地區分類
    - 北非
    - 中非
    - 南部非洲

第8章競爭情勢

Bristol-Myers Squibb Company
GlycoMimetics Inc.
Pfizer Inc.
Anthera Pharmaceuticals Inc.
Eli Lilly and Company
Mast Therapeutics
Daiichi Sankyo Company Ltd.
Novartis International AG
Bluebird Bio Inc.
HemaQuest Pharmaceuticals Inc.
Emmaus Medical Inc.
Baxter International Inc.
Prolong Pharmaceuticals
Medunik USA Inc.
Sangamo Therapeutics, Inc.
Global Blood Therapeutics
Alnylam Pharmaceuticals
Acceleron Pharma, Inc.

第9章

分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI4059

Hemoglobinopathy Treatment Drugs Market is estimated to be valued at USD 5.74 Bn in 2026 and is expected to reach USD 10.24 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 5.74 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.60%	2033 Value Projection:	USD 10.24 Bn

The hemoglobinopathies encompass all genetic diseases of hemoglobin. They fall into two main groups: thalassemia syndromes and structural hemoglobin variants (abnormal hemoglobins). a and B thalassemia are the main types of thalassemia; the main structural hemoglobin variants are HbS, HbE, and HbC. There are many subtypes and combined types in each group. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Stem-cell transplantation is the preferred treatment for severe forms of thalassemia. Supportive, rather than curative, treatment consists of periodic blood transfusions for life combined with iron chelation. Drugs to treat the symptoms of sickle-cell disease include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. Blood transfusions should be given only when strictly indicated. More than 90% of patients currently survive into adulthood. Optimally treated patients have a projected life span of 50 to 60 years. With approximately 7% of the worldwide population being carriers, hemoglobinopathies are the most common monogenic diseases and one of the world's major health problems. They were originally found mainly in the Mediterranean area and large parts of Asia and Africa. International migration has spread them from those areas all over the world. In many parts of Europe today, hemoglobin (Hb) defects are classified as endemic diseases.

Market Dynamics

Increasing launches of new products and mergers and acquisitions by key market players are expected to drive the global hemoglobinopathy treatment drugs market growth. For instance, on August 8, 2022, Pfizer Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, and Global Blood Therapeutics, Inc., a U.S.-based Healthcare company, announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer Inc will acquire all the outstanding shares of Global Blood Therapeutics, Inc. for US$ 68.50 per share in cash, for a total enterprise value of approximately US$ 5.4 billion, including debt and net of cash acquired. The Boards of Directors of both companies have unanimously approved the transaction.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemoglobinopathy treatment drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Baxter International Inc., Prolong Pharmaceuticals, Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
Global hemoglobinopathy treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemoglobinopathy treatment drugs market

Detailed Segmentation:

Global Hemoglobinopathy Treatment Drugs Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
Global Hemoglobinopathy Treatment Drugs Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hemoglobinopathy Treatment Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia Pacific
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
Bristol-Myers Squibb Company
GlycoMimetics Inc.
Pfizer Inc.
Anthera Pharmaceuticals Inc.
Eli Lilly and Company
Mast Therapeutics
Daiichi Sankyo Company Ltd.
Novartis International AG
Bluebird Bio Inc.
HemaQuest Pharmaceuticals Inc.
Emmaus Medical Inc.
Baxter International Inc.
Prolong Pharmaceuticals
Medunik USA Inc.
Sangamo Therapeutics, Inc.
Global Blood Therapeutics, Inc.
Alnylam Pharmaceuticals
Acceleron Pharma, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Hemoglobinopathy Treatment Drugs Market, By Drug Type, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Hydroxyurea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)

5. Global Hemoglobinopathy Treatment Drugs Market, By Disease Type, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Sickle Cell Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Other Hb Variants Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)

6. Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)

7. Global Hemoglobinopathy Treatment Drugs Market, By Region, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022-2033
Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021-2033, (US$ Billion)

8. Competitive Landscape

Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlycoMimetics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Anthera Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mast Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Daiichi Sankyo Company Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bluebird Bio Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
HemaQuest Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Emmaus Medical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Prolong Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Medunik USA Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Sangamo Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Global Blood Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Alnylam Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Acceleron Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies